Inside information: Preliminary result of Suominen Corporation’s oversubscribed rights issue

Suominen completed a rights offering of 77,121,272 new shares at EUR 0.36 per share, targeting gross proceeds of ~EUR 28m. Preliminary results show 81,472,405 new shares were subscribed for (~105.6% of the offer), including 74,827,292 shares via subscription rights and 6,645,113 shares without rights—an oversubscription. Management says proceeds will accelerate its “Full Potential Program” to improve production/supply reliability and commercial capabilities, while strengthening the capital structure; final results are due around 2 July 2026.

Analysis

This is primarily a balance-sheet repair, not a clean operating inflection. The equity raise is large relative to the float, so per-share economics stay under pressure even if the company has bought itself time; that usually caps any durable rerating until there is proof of margin and cash conversion. The oversubscription matters more as a signal that existing holders are choosing dilution over financing risk, which lowers near-term default/tail risk but does not yet prove the business model is fixed.

Near term, the most likely market mechanism is technical: rights sellers, interim-share conversion, and new-share delivery can create a short-lived air pocket or relief rally unrelated to fundamentals. Over 1-3 months, the key catalyst is whether the capital infusion actually reduces working-capital stress and stabilizes plant reliability; if not, the market will quickly reprice this as a bridge to another dilution event. Over 6-18 months, the only durable upside comes from sustained margin expansion, otherwise the larger share count just spreads a still-mediocre enterprise value across more equity.

Second-order winners are creditors and customers that rely on continuity; competitors may see less opportunistic share capture from a forced seller. The contrarian point is that a successful rights issue can be mildly bullish for solvency but still bearish for the stock if the operating fix is slower than investors expect. The thesis is falsified if post-raise net leverage does not improve by the next quarterly update or if management does not show sequential EBITDA/FCF improvement into Q3-Q4.

Key Decisions for Investors

• SUY1V: do not chase the stock before the new shares begin trading on/around 6 Jul; wait for 3-5 sessions of volume normalization. If it holds above implied TERP by >8-10%, consider a small tactical long with a 10-12% stop below that level; otherwise the dilution overhang likely wins.
• SUY1V: if there is a post-listing relief rally into the first week of trading, fade strength rather than add; risk/reward is asymmetric because the new share count is ~57% of post-offering shares, so upside is capped until operating data improves.
• MATV or BERY: modest relative-value long versus SUY1V only if you want exposure to nonwovens without balance-sheet risk. Favor the larger, liquid names as cleaner ways to own any sector stabilization; SUY1V needs a separate turnaround catalyst.
• NRDBY: no trade. The underwriting/fee income impact is too small to matter, and this event is not a reason to re-rate Nordic bank earnings.